• In early June 2026, Amneal Pharmaceuticals reported positive interim Phase 4 ELEVATE-PD results for CREXONT in Parkinson’s disease and also received FDA approval, with 180 days of Competitive Generic Therapy exclusivity, for its romidepsin injection solution for cutaneous T-cell lymphoma.
• The CREXONT data highlighted meaningful gains in “Good On” time and motor control across prior treatment groups, while the romidepsin approval brought an oncology medicine back to the U.S. market in a ready-to-use format that can simplify hospital and pharmacy workflows.
• We’ll now examine how CREXONT’s Phase 4 outcomes could influence Amneal’s investment narrative around branded expansion and complex therapies.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free.

Amneal Pharmaceuticals Investment Narrative Recap

To own Amneal, you have to believe its shift toward branded and complex therapies can steadily improve its mix beyond a pressured U.S. generics base, while it manages leverage and pricing risk. The strong interim CREXONT data reinforces that branded Parkinson’s could support this narrative, but it does not fundamentally change the near term focus on executing launches and managing U.S. generic price pressure.

Among recent developments, the FDA approval of Amneal’s romidepsin injection solution with 180 days of Competitive Generic Therapy exclusivity stands out. It underscores the company’s push into higher value injectables, which sits alongside CREXONT as part of the same effort to lean more on differentiated products rather than purely volume driven generics.

Yet even as CREXONT and romidepsin expand Amneal’s branded and complex portfolio, investors should be aware that...

Amneal Pharmaceuticals’ narrative projects $3.7 billion revenue and $325.7 million earnings by 2029.

Uncover how Amneal Pharmaceuticals' forecasts yield a $17.20 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Three Simply Wall St Community fair value estimates span roughly US$11.94 to US$82.75 per share, showing how far apart individual views can be. That spread sits against a business still heavily exposed to U.S. generics pricing pressure, which many investors see as a key factor for Amneal’s longer term performance and are encouraged to explore in more detail.

Explore 3 other fair value estimates on Amneal Pharmaceuticals - why the stock might be worth 22% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Amneal Pharmaceuticals research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Amneal Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amneal Pharmaceuticals' overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
• Find 47 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.